Prime Therapeutics research shows that persistence with GLP-1 weight-loss therapies continues to improve, offering new insights into long-term treatment trends and outcomes

Report encourages providers to consider health contexts and lifestyle modifications as well as personal preferences and current guidelines when prescribing GLP-1s for weight loss

Editorial team nisoldipine (Sular) Drug Approvals July 31, 2026 — rituximab-cdxx (Zimrixby) BLA approval; 100 mg/10 mL (10 mg/mL) injection in a single-dose vial for IV use and 500 mg/50 mL (10...

References Annual review of factor replacement products. Oklahoma Health Care Authority Review Board. Updated April 2016. https://oklahoma.gov/ohca.html. Accessed April 1, 2022. Burke T, Asghar S,...